Home Featured Page 220

Featured

Latest

Q1 2026 Psychedelic Patent Update

The Psychedelic Practitioner Issue 4: Integration

Shane Mauss – Comedy and Molecules – Episode 14

March 2026 Psychedelic Bill Round-up

Ketamine-Assisted Couple Therapy Training by Enamory

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development...

Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully...

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development...

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker...

Braxia Scientific Graduates First Cohort of Medical Professionals from Psilocybin-Assisted Therapy...

U.S. FDA Approves Nova Mentis Orphan Drug Application

Cybin Hosting Research and Development Briefing on November 8, 2021

Filament Health Announces FDA Authorization of Clinical Trial with First-Ever Direct...

Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results...

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in...

EDITOR PICKS

Q1 2026 Psychedelic Patent Update

The Psychedelic Practitioner Issue 4: Integration

Shane Mauss – Comedy and Molecules – Episode 14

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Q1 2026 Psychedelic Patent Update

The Psychedelic Practitioner Issue 4: Integration

Shane Mauss – Comedy and Molecules – Episode 14

March 2026 Psychedelic Bill Round-up

Ketamine-Assisted Couple Therapy Training by Enamory

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development...

Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully...

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development...

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker...

Braxia Scientific Graduates First Cohort of Medical Professionals from Psilocybin-Assisted Therapy...

U.S. FDA Approves Nova Mentis Orphan Drug Application

Cybin Hosting Research and Development Briefing on November 8, 2021

Filament Health Announces FDA Authorization of Clinical Trial with First-Ever Direct...

Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results...

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in...

EDITOR PICKS

Q1 2026 Psychedelic Patent Update

The Psychedelic Practitioner Issue 4: Integration

Shane Mauss – Comedy and Molecules – Episode 14

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY